Similarly, Olsson et al. [13] also opined the nonassociation of UGT2B17 polymorphism with prostate cancer risk and, recently, Chew et al. [12] disregarded homozygous deletion genotype of UGT2B17 with osteoporosis risk. This evidence concerns the gene UGT2B17 and prostate cancer.